Age

18–any

Sex

MALE

Healthy volunteers

Not accepted

Aged ≥ 18 years old;
Men with histologically or cytologically confirmed adenocarcinoma of the prostate with evidence of metastases;
ECOG performance status ≤2;
Staging of disease with TC + bone scintigraphy or with PET PSMA/choline;
Availability of baseline PSA and after six months (±1) from the beginning of the ADT;
Ongoing or completed treatment with at least one ARPI among abiraterone acetate, apalutamide, darolutamide and enzalutamide;
Adequate information about baseline demographic, biological, clinical and laboratory data;
Signed informed consent form, or declaration in lieu of informed consent form, if applicable.

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer